Compare GSK plc (GSK) vs Procter & Gamble Co (PG) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Procter & Gamble (PG) trades at $150.28, up 2.85% over the past 24 hours, with technical indicators showing a neutral trend near key resistance at $150. The company reported steady revenue of $84.28B in 2025 and has beaten EPS estimates for three consecutive quarters, demonstrating resilient profitability with a net margin of 19.16%. Recent corporate developments include a new WNBA partnership and consistent dividend payments of $1.09 per share.

PG offers stability with strong cash flow and a 69-year dividend growth track record, but premium valuation multiples and modest revenue growth pose near-term upside limitations. Analyst consensus leans bullish with a $161.71 price target, though competitive pressures and economic sensitivity remain key risks for investors seeking defensive exposure.